Greenwich LifeSciences Inc
Research Greenwich LifeSciences Inc (GLSI) on Bullrun: market cap USD 260.83M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGLSI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 260.83M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 3.95M
- Free cash flow-USD 1.94M
Valuation Snapshot
latest market cap is USD 260.83M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 19.36M | -USD 9.91M | n/a | -1.43 | USD 6.18M | n/a | USD 353.22K |
| FY2024 | USD 0 | -USD 17.41M | -USD 7.27M | n/a | -1.34 | USD 4.09M | n/a | USD 908.63K |
| FY2023 | USD 0 | -USD 8.89M | -USD 6.48M | n/a | -0.69 | USD 6.99M | n/a | USD 6.70M |
| FY2022 | USD 0 | -USD 7.83M | -USD 6.20M | n/a | -0.61 | USD 13.47M | n/a | USD 13.21M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 260.83M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 291.08M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 147.70M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 135.16M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 195.29M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 319.89M | n/a | n/a | n/a |
About Greenwich LifeSciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Greenwich LifeSciences Inc's market cap?
Greenwich LifeSciences Inc's market capitalization is USD 260.83M.
What does Greenwich LifeSciences Inc do?
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc.